Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIb and IV non-small-cell lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 5, 1998, Pages 438-441

  Kindler, Hedy L ^a,e   Kris, Mark G ^a   Smith, Ian E ^b   Miller, Vincent A ^a   Grant, Stefan C ^a   Krebs, Jacqueline B ^c   Ross, Graham A ^c   Slevin, Maurice L ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Non small cell lung cancer; Phase II trials; Topotecan

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER STAGING; CANCER SURVIVAL; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DNA TOPOISOMERASES, TYPE I; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSION PUMPS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; TOPOTECAN;

EID: 0031784642     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199810000-00003     Document Type: Article

References (12)

1. Slichenmeyer WJ, Rowinsky EK, Donehower RC, SH Kaufmann. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993;85:271-91.
2. Von Hoff DD, Burris III HA, Eckardt J, et al. Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol 1994;34:541-545.
3. Burris III HA, Hanauske AR, Johnson RK, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony forming units. J Natl Cancer Inst 1992;84:1816-20.
4. Rowinsky EK, Grochow LB, Hendricks CB, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992;10:647-56.
5. Perez-Soler R, Fossella FV, Glisson BS, et al. Phase II study of topotecan in patients with advanced non-small cell lung cancer previously untreated with chemotherapy. J Clin Oncol 1996;14:503-13.
6. Lynch TJ Jr, Kalish L, Strauss G, et al. Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 1994;12:347-52.
7. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996;14:3056-61.
8. Schiller JH, Kim KM, Hutson P, et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1996;14:2345-52.
9. Perez-Soler R, Khuri F, Pisters KM, et al. Phase II study of topotecan in patients with squamous carcinoma of the lung previously untreated with chemotherapy [Abstract]. Proceedings of the American Society of Clinical Oncology 1997;16:450a.
10. Weitz JJ, Jung S-H, Marschke Jr RF, et al. Randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung carcinoma (NSCLC): a North Central Cancer Treatment Group (NCCTG) trial [Abstract]. Proceedings of the American Society of Clinical Oncology 1995;14:348.
11. Hochster H, Liebes L, Speyer J, et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994;12:553-9.
12. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. Journal of the American Statistical Association 1958;53:457-81.